A research and training program for junior clinicians in treating metastatic mela View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2013-2019

FUNDING AMOUNT

780420 USD

ABSTRACT

DESCRIPTION (provided by applicant): This K24 application is to support my career development as I build a translational research program. I am an associate professor, seeing patients with melanoma and renal cell carcinoma. I mentor junior faculty and clinical fellows and run an R-01 funded research laboratory, conducting biomarker studies and pre-clinical drug testing experiments in these two diseases. I have a busy clinical practice and actively enroll patients on clinical trials. Given the increased incidence of metastatic melanoma and the high frequency of brain metastases (BrMs) in this population, there is urgent need for new approaches to this problem, as most clinical trials exclude BrMs patients, and their therapeutic options are exceedingly limited. I recently assembled a group of clinical and basic science researchers that focus on BrMs, and my vision (and long term goal) is to develop a brain metastasis research center at Yale. My short term goal is to conduct our first two BrMs-specific protocols and to generate preclinical data for future trials. To accomplish my goals, I need additional protected time to conduct these studies and mentor junior clinicians to participate these efforts. My proposed career development plan includes both acquisition of new skills and a plan for increased mentorship of junior faculty and clinical fellows. The former involves formal training such as a didactic statistics course and informal training in animal experiments and additional training in development of phase I trials. In addition to mentorship of fellows, I will mentor junior faculty, including two current mentees and two new hires. I will participate in specific mentorship activities at Yale supported by the CTSA grant, including advisory committees and lectures. The underlying premise of this proposal is that drug penetration through the leaky vessels found in BrMs can be superior to typical BBB penetration. We further hypothesize that use of combinations of local therapies and molecular targeted therapies selected based on individual tumor characteristics will result in improved survival of patients wit BrMs, similar to patients with other visceral metastases. Finally, manipulation of brain immunity might be a means of treating brain metastases. My first aim includes the first neoadjuvant clinical trial using a targeted therapy (vemurafenib) and innovative surgical approaches to treat patients with brain metastases not amenable to gamma-knife therapy. Predictive biomarker studies will be incorporated, complimented by lab-based endeavors to train mentees in conducting pre-clinical drug sensitivity studies with an emphasis on BrMs, with the goal of developing a pipeline of drugs to be studied in future BrM trials. In aim 2, I will mentor a junior faculty clinician in conducting a clinical trial of an antibody against an immune-checkpoint inhibitory molecule (PD-1), and development of a panel of predictive biomarkers. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=9279067

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "780420"
    }, 
    "description": "DESCRIPTION (provided by applicant): This K24 application is to support my career development as I build a translational research program. I am an associate professor, seeing patients with melanoma and renal cell carcinoma. I mentor junior faculty and clinical fellows and run an R-01 funded research laboratory, conducting biomarker studies and pre-clinical drug testing experiments in these two diseases. I have a busy clinical practice and actively enroll patients on clinical trials. Given the increased incidence of metastatic melanoma and the high frequency of brain metastases (BrMs) in this population, there is urgent need for new approaches to this problem, as most clinical trials exclude BrMs patients, and their therapeutic options are exceedingly limited. I recently assembled a group of clinical and basic science researchers that focus on BrMs, and my vision (and long term goal) is to develop a brain metastasis research center at Yale. My short term goal is to conduct our first two BrMs-specific protocols and to generate preclinical data for future trials. To accomplish my goals, I need additional protected time to conduct these studies and mentor junior clinicians to participate these efforts. My proposed career development plan includes both acquisition of new skills and a plan for increased mentorship of junior faculty and clinical fellows. The former involves formal training such as a didactic statistics course and informal training in animal experiments and additional training in development of phase I trials. In addition to mentorship of fellows, I will mentor junior faculty, including two current mentees and two new hires. I will participate in specific mentorship activities at Yale supported by the CTSA grant, including advisory committees and lectures. The underlying premise of this proposal is that drug penetration through the leaky vessels found in BrMs can be superior to typical BBB penetration. We further hypothesize that use of combinations of local therapies and molecular targeted therapies selected based on individual tumor characteristics will result in improved survival of patients wit BrMs, similar to patients with other visceral metastases. Finally, manipulation of brain immunity might be a means of treating brain metastases. My first aim includes the first neoadjuvant clinical trial using a targeted therapy (vemurafenib) and innovative surgical approaches to treat patients with brain metastases not amenable to gamma-knife therapy. Predictive biomarker studies will be incorporated, complimented by lab-based endeavors to train mentees in conducting pre-clinical drug sensitivity studies with an emphasis on BrMs, with the goal of developing a pipeline of drugs to be studied in future BrM trials. In aim 2, I will mentor a junior faculty clinician in conducting a clinical trial of an antibody against an immune-checkpoint inhibitory molecule (PD-1), and development of a panel of predictive biomarkers.", 
    "endDate": "2019-06-30T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.48336.3a", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2420951", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2420951"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "K24CA172123"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "metastatic melanoma", 
      "groups", 
      "use", 
      "addition", 
      "new approach", 
      "junior faculty clinician", 
      "pipeline", 
      "junior faculty", 
      "mentors", 
      "basic science researchers", 
      "K24 application", 
      "therapeutic options", 
      "proposed career development plan", 
      "first aim", 
      "pre-clinical drug testing experiments", 
      "therapy", 
      "Aim 2", 
      "melanoma", 
      "local therapy", 
      "additional training", 
      "gamma-knife therapy", 
      "efforts", 
      "preclinical data", 
      "formal training", 
      "manipulation", 
      "informal training", 
      "future BrM trials", 
      "combination", 
      "individual tumor characteristics", 
      "incidence", 
      "goal", 
      "clinical trials", 
      "Yale", 
      "BrMs patients", 
      "disease", 
      "CTSA grants", 
      "premise", 
      "new skills", 
      "drugs", 
      "PD-1", 
      "biomarker studies", 
      "BrMs-specific protocols", 
      "plan", 
      "phase I trial", 
      "renal cell carcinoma", 
      "predictive biomarkers", 
      "clinical fellows", 
      "R-01", 
      "brain immunity", 
      "associate professor", 
      "didactic statistics course", 
      "lab", 
      "future trials", 
      "vision", 
      "antibodies", 
      "junior clinicians", 
      "research", 
      "emphasis", 
      "immune-checkpoint inhibitory molecule", 
      "mentorship", 
      "development", 
      "mentees", 
      "training program", 
      "metastatic mela", 
      "BRMS", 
      "leaky vessels", 
      "lectures", 
      "fellows", 
      "translational research program", 
      "brain metastasis research center", 
      "acquisition", 
      "short term goals", 
      "specific mentorship activities", 
      "typical BBB penetration", 
      "busy clinical practice", 
      "most clinical trials", 
      "innovative surgical approach", 
      "study", 
      "high frequency", 
      "research laboratories", 
      "drug penetration", 
      "pre-clinical drug sensitivity studies", 
      "endeavor", 
      "proposal", 
      "predictive biomarker studies", 
      "Advisory Committee", 
      "time", 
      "animal experiments", 
      "problem", 
      "urgent need", 
      "current mentees", 
      "population", 
      "other visceral metastases", 
      "career development", 
      "first neoadjuvant clinical trial", 
      "description", 
      "applicants", 
      "new hires", 
      "patients", 
      "means", 
      "brain metastases", 
      "vemurafenib", 
      "panel", 
      "improved survival", 
      "long term goal"
    ], 
    "name": "A research and training program for junior clinicians in treating metastatic mela", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.47100.32", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": "YALE UNIVERSITY", 
          "type": "Organization"
        }, 
        "familyName": "KLUGER", 
        "givenName": "HARRIET M", 
        "id": "sg:person.01336750727.45", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.01336750727.45", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2420951"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T12:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_3.xml.gz", 
    "startDate": "2013-07-01T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=9279067"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2420951'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2420951'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2420951'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2420951'


 

This table displays all metadata directly associated to this object as RDF triples.

149 TRIPLES      19 PREDICATES      127 URIs      119 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.2420951 schema:about anzsrc-for:2211
2 schema:amount Nd059f8336f3644b5b6c28bb4154d919c
3 schema:description DESCRIPTION (provided by applicant): This K24 application is to support my career development as I build a translational research program. I am an associate professor, seeing patients with melanoma and renal cell carcinoma. I mentor junior faculty and clinical fellows and run an R-01 funded research laboratory, conducting biomarker studies and pre-clinical drug testing experiments in these two diseases. I have a busy clinical practice and actively enroll patients on clinical trials. Given the increased incidence of metastatic melanoma and the high frequency of brain metastases (BrMs) in this population, there is urgent need for new approaches to this problem, as most clinical trials exclude BrMs patients, and their therapeutic options are exceedingly limited. I recently assembled a group of clinical and basic science researchers that focus on BrMs, and my vision (and long term goal) is to develop a brain metastasis research center at Yale. My short term goal is to conduct our first two BrMs-specific protocols and to generate preclinical data for future trials. To accomplish my goals, I need additional protected time to conduct these studies and mentor junior clinicians to participate these efforts. My proposed career development plan includes both acquisition of new skills and a plan for increased mentorship of junior faculty and clinical fellows. The former involves formal training such as a didactic statistics course and informal training in animal experiments and additional training in development of phase I trials. In addition to mentorship of fellows, I will mentor junior faculty, including two current mentees and two new hires. I will participate in specific mentorship activities at Yale supported by the CTSA grant, including advisory committees and lectures. The underlying premise of this proposal is that drug penetration through the leaky vessels found in BrMs can be superior to typical BBB penetration. We further hypothesize that use of combinations of local therapies and molecular targeted therapies selected based on individual tumor characteristics will result in improved survival of patients wit BrMs, similar to patients with other visceral metastases. Finally, manipulation of brain immunity might be a means of treating brain metastases. My first aim includes the first neoadjuvant clinical trial using a targeted therapy (vemurafenib) and innovative surgical approaches to treat patients with brain metastases not amenable to gamma-knife therapy. Predictive biomarker studies will be incorporated, complimented by lab-based endeavors to train mentees in conducting pre-clinical drug sensitivity studies with an emphasis on BrMs, with the goal of developing a pipeline of drugs to be studied in future BrM trials. In aim 2, I will mentor a junior faculty clinician in conducting a clinical trial of an antibody against an immune-checkpoint inhibitory molecule (PD-1), and development of a panel of predictive biomarkers.
4 schema:endDate 2019-06-30T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.48336.3a
6 schema:identifier N62d465ad5e56493785b381a6a97e3adc
7 Nf106d64829234caba09b7a1869681918
8 schema:inLanguage en
9 schema:keywords Advisory Committee
10 Aim 2
11 BRMS
12 BrMs patients
13 BrMs-specific protocols
14 CTSA grants
15 K24 application
16 PD-1
17 R-01
18 Yale
19 acquisition
20 addition
21 additional training
22 animal experiments
23 antibodies
24 applicants
25 associate professor
26 basic science researchers
27 biomarker studies
28 brain immunity
29 brain metastases
30 brain metastasis research center
31 busy clinical practice
32 career development
33 clinical fellows
34 clinical trials
35 combination
36 current mentees
37 description
38 development
39 didactic statistics course
40 disease
41 drug penetration
42 drugs
43 efforts
44 emphasis
45 endeavor
46 fellows
47 first aim
48 first neoadjuvant clinical trial
49 formal training
50 future BrM trials
51 future trials
52 gamma-knife therapy
53 goal
54 groups
55 high frequency
56 immune-checkpoint inhibitory molecule
57 improved survival
58 incidence
59 individual tumor characteristics
60 informal training
61 innovative surgical approach
62 junior clinicians
63 junior faculty
64 junior faculty clinician
65 lab
66 leaky vessels
67 lectures
68 local therapy
69 long term goal
70 manipulation
71 means
72 melanoma
73 mentees
74 mentors
75 mentorship
76 metastatic mela
77 metastatic melanoma
78 most clinical trials
79 new approach
80 new hires
81 new skills
82 other visceral metastases
83 panel
84 patients
85 phase I trial
86 pipeline
87 plan
88 population
89 pre-clinical drug sensitivity studies
90 pre-clinical drug testing experiments
91 preclinical data
92 predictive biomarker studies
93 predictive biomarkers
94 premise
95 problem
96 proposal
97 proposed career development plan
98 renal cell carcinoma
99 research
100 research laboratories
101 short term goals
102 specific mentorship activities
103 study
104 therapeutic options
105 therapy
106 time
107 training program
108 translational research program
109 typical BBB penetration
110 urgent need
111 use
112 vemurafenib
113 vision
114 schema:name A research and training program for junior clinicians in treating metastatic mela
115 schema:recipient Nebc6dacd271d49feadc32975c7b6a80e
116 sg:person.01336750727.45
117 https://www.grid.ac/institutes/grid.47100.32
118 schema:sameAs https://app.dimensions.ai/details/grant/grant.2420951
119 schema:sdDatePublished 2019-03-07T12:10
120 schema:sdLicense https://scigraph.springernature.com/explorer/license/
121 schema:sdPublisher N345ce57d3b754f9a966f3b6b295bbf27
122 schema:startDate 2013-07-01T00:00:00Z
123 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=9279067
124 sgo:license sg:explorer/license/
125 sgo:sdDataset grants
126 rdf:type schema:MonetaryGrant
127 N345ce57d3b754f9a966f3b6b295bbf27 schema:name Springer Nature - SN SciGraph project
128 rdf:type schema:Organization
129 N62d465ad5e56493785b381a6a97e3adc schema:name nih_id
130 schema:value K24CA172123
131 rdf:type schema:PropertyValue
132 Nd059f8336f3644b5b6c28bb4154d919c schema:currency USD
133 schema:value 780420
134 rdf:type schema:MonetaryAmount
135 Nebc6dacd271d49feadc32975c7b6a80e schema:member sg:person.01336750727.45
136 schema:roleName PI
137 rdf:type schema:Role
138 Nf106d64829234caba09b7a1869681918 schema:name dimensions_id
139 schema:value 2420951
140 rdf:type schema:PropertyValue
141 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
142 rdf:type schema:DefinedTerm
143 sg:person.01336750727.45 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
144 schema:familyName KLUGER
145 schema:givenName HARRIET M
146 rdf:type schema:Person
147 https://www.grid.ac/institutes/grid.47100.32 schema:name YALE UNIVERSITY
148 rdf:type schema:Organization
149 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...